Manufactured Object – Page 28

Fujifilm Diosynth Biotechnologies, $1.2 billion expansion, North Carolina, Holly Springs, 1/400 jobs, Biopharmaceutical manufacturing, End-to-end cell culture CDMO facility, Japanese investment

US Drug Shortages Hit Record High Since 2001: ASHP Report

1 year ago talkbio0Tagged ASHP, Attention deficit hyperactivity disorder, Biden administration, Central Nervous System Stimulants, Chemotherapy Drugs Adminstered, controlled substance, Defense Production Act, DPA, Drug Enforcement Administration, Drug shortages, hormone agents, Hospitals, Incentives, intravenous fluids, Microbicides, Quality concerns, Record high, American Society of Health-System Pharmacists, shortage, Supply Chain Resilience, White House Council

Drug shortages, Record high, American Society of Health-System Pharmacists (ASHP), 323 drugs in shortage, Chemotherapy drugs, ADHD therapies, Central nervous system stimulants, Antimicrobials, Hormone agents, Intravenous fluids, Drug Enforcement Administration (DEA), Biden administration, White House Council on Supply Chain Resilience, Defense Production Act (DPA), Incentives for hospitals, Quality concerns, Controlled substances

Gilead Partners with Xilio Therapeutics for Novel Tumor-Activated IL-12 Program

1 year ago talkbio0Tagged development aspects, interleukin-12, Xilio, XTX301

interleukin-12, Xilio, XTX301, development aspects

Walgreens Takes $6 Billion Hit from VillageMD Investment Amid Strategic Review

1 year ago talkbio0Tagged Clinic, Cost Savings Plan, Investment Value Decline, Quarter 2, strategic review, VillageMD, Walgreens, Write-down

Walgreens, VillageMD, Quarter 2, $6 billion loss, Write-down, Investment Value Decline, Strategic Review, Cost Savings Plan, Underperforming Clinics Closure

Alexion Expands Indications for Long-Acting C5 Complement Inhibitor Ultomiris in Rare Autoimmune Disorder NMOSD

1 year ago talkbio0Tagged Alexion, Annals, Approved, AstraZeneca Rare Disease, C5 complement inhibitor, CHAMPIER-NMOSD trial, generalised myasthenia gravis, gMG, long-acting, Marc Dunoyer, Neurology speciality, Neuromyelitis Optica, Paroxysmal nocturnal hemoglobinuria, Publications, ravulizumab-cwvz, Ultomiris, United States Food and Drug Administration

Ultomiris, ravulizumab-cwvz, C5 complement inhibitor, neuromyelitis optica spectrum disorder (NMOSD), FDA approval, long-acting, zero relapses, CHAMPIER-NMOSD trial, Annals of Neurology publication, Marc Dunoyer, AstraZeneca Rare Disease, Alexion, generalised myasthenia gravis (gMG), paroxysmal nocturnal haemoglobinuria (PNH).

Takeda’s $5.2B Ariad Deal Yields Label Expansion for Iclusig in Rare Leukemia

1 year ago talkbio0Tagged 5.2B, Ariad, expansion, Iclusig, Infrequent, Labels (device), leukemia, Takeda

Takeda, Ariad, $5.2B deal, Iclusig, Label expansion, Rare form of leukemia